


**Product Name** : ADH-503  
**Cat. No.** : PC-72987  
**CAS No.** : 2055362-72-4  
**Molecular Formula** : C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub>  
**Molecular Weight** : 524.65  
**Target** : Other Targets  
**Solubility** :



## Biological Activity

ADH-503 (ADH503) is a small-molecule allosteric agonist of CD11b that can render tumors more sensitive to checkpoint blockade.

ADH-503 rapidly decreased the genes involved in IL-1 signaling, increased the expression of cytokines involved in T cell and DC trafficking.

ADH-503 reduced the regulatory T cell (Treg) recruitment of cytokines CCL17 and CCL22 in PDAC-activated macrophages, down-regulated TGF- $\beta$ 1, IL-1 $\alpha$ , and IL-1 $\beta$  and reduced alternative activation markers arginase-1 (Arg1), YM1, and Retn $\alpha$  while upregulating type I interferons (IFN $\alpha$ 1 and IFN $\beta$ ) and T cell recruitment factors (CXCL9, CXCL10, and CXCL11).

ADH-503 reduced the numbers of total tumor-infiltrating CD11b+ cells and subsets of CD11b+ monocytes, granulocytes, eosinophils, and macrophages on myeloid cells, improves T cell responses in vivo, induces the accumulation of CD103+ cDCs in the tumor.

ADH-503 impairs tumor growth and improves survival in orthotopic models and KPC GEMMs, also improves the efficacy of chemotherapy.

## References

Panni RZ, et al. Sci Transl Med. 2019 Jul 3;11(499). pii: eaau9240. doi: 10.1126/scitranslmed.aau9240.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com